Research map: Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial

Back to the article

Papers in this map

  1. The end of AIDS: HIV infection as a chronic disease · Steven G. Deeks · 2013 · 2126 citations · Cited by this paper
  2. A Nonsporulating Sinonasal Culprit · 2026 · Related
  3. Clinical targeting of HIV capsid protein with a long-acting small molecule · John O. Link · 2020 · 448 citations · Cited by this paper
  4. Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers · 2026 · Related
  5. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection · Sorana Segal‐Maurer · 2022 · 331 citations · Cited by this paper
  6. Fowling in the Marshes · 2026 · Related
  7. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults · Sherene Min · 2011 · 221 citations · Cited by this paper
  8. Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin · 2026 · Related
  9. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study · Hugo Jourdain · 2022 · 104 citations · Cited by this paper
  10. Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy · 2026 · Related
  11. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study · Nicolas Margot · 2022 · 60 citations · Cited by this paper
  12. Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial · 2026 · Related
  13. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States · Mary Clare Masters · 2019 · 44 citations · Cited by this paper
  14. Challenging Weight-Tiered Antibiotic Prophylaxis in Obese Patients Undergoing Colorectal Surgery Using Computed Tomography-Derived Body Composition · 2026 · Related
  15. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial · Onyema Ogbuagu · 2024 · 42 citations · Cited by this paper
  16. Detection-Dependent Classification of Valve Strands: How Much Does Imaging Intensity Drive the “Noninfective Endocarditis” Diagnosis? · 2026 · Related
  17. Compensatory Substitutions in the HIV-1 Capsid Reduce the Fitness Cost Associated with Resistance to a Capsid-Targeting Small-Molecule Inhibitor · Jiong Shi · 2014 · 36 citations · Cited by this paper
  18. The New Vaccine Surveillance Network: 25 Years of Active, Population-Based Surveillance for Pediatric Infectious Diseases in the United States · 2026 · Related
  19. Impact of long-acting therapies on the global HIV epidemic · Nomathemba C. Chandiwana · 2021 · 36 citations · Cited by this paper
  20. Sepsis Diagnostic Excellence and Its Association With Mortality in Adults With Potential Infection · 2026 · Related
  21. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals · Alex Durand Nka · 2022 · 31 citations · Cited by this paper
  22. Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV · Morgan Mari Philbin · 2022 · 30 citations · Cited by this paper
  23. The Role of Capsid in the Early Steps of HIV-1 Infection: New Insights into the Core of the Matter · Nawal AlBurtamani · 2021 · 21 citations · Cited by this paper
  24. Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir · Catia Marzolini · 2024 · 10 citations · Cited by this paper
  25. Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV · Debbie P. Hagins · 2025 · 7 citations · Cited by this paper
  26. Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499 · Chunfu Wang · 2025 · 5 citations · Cited by this paper
  27. Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV · Nilay Thakkar · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)